Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 shows clinical signal disease relevance led by congestive heart failure. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P16615. Start with congestive heart failure, then reuse UniProt P16615 as the stable protein anchor across project notes and exports.
Start with congestive heart failure, then reuse UniProt P16615 as the stable protein anchor across project notes and exports.
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 shows clinical signal disease relevance led by congestive heart failure. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with congestive heart failure because it currently carries clinical signal support. Linked drugs include ISTAROXIME. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxySarcoplasmic/endoplasmic reticulum calcium ATPase 2
Review this target as Sarcoplasmic/endoplasmic reticulum calcium ATPase 2, mapped to UniProt P16615. Sequence length is 1042 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 as ChEMBL target CHEMBL3901, mapped to UniProt P16615. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 is the right protein anchor across sources, using UniProt P16615 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why congestive heart failure is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P16615 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 |
| UniProt Accession | P16615 |
| Component Type | Protein |
| Sequence Length | 1042 aa |
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2
Review this target as Sarcoplasmic/endoplasmic reticulum calcium ATPase 2, mapped to UniProt P16615. Sequence length is 1042 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 shows clinical signal disease relevance led by congestive heart failure. 2 more disease programs remain visible in the same review block.
Start review with congestive heart failure because it currently carries clinical signal support. Linked drugs include ISTAROXIME. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4514624 | 8.89 | Ki | 1.3 | Preclinical |
| CHEMBL4207081 | 7.96 | Ki | 11.0 | Preclinical |
| CHEMBL5435124 | 7.8 | EC50 | 16.0 | Preclinical |
| CHEMBL5653589 | 7.63 | Kd | 23.16 | Preclinical |
| CHEMBL4216774 | 7.57 | Ki | 27.0 | Preclinical |
| CHEMBL468766 | 7.05 | IC50 | 90.0 | Preclinical |
| CHEMBL4534285 | 6.68 | IC50 | 210.0 | Preclinical |
| CHEMBL480626 | 5.7 | IC50 | 2000.0 | Preclinical |
| CHEMBL410063 | 5.3 | IC50 | 5000.0 | Preclinical |
| CHEMBL140 | 5.16 | IC50 | 7000.0 | Clinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 13 | 5 | 7.4 |
| subcellular format | 3 | 1 | 7.8 |
| cell-based format | 2 | 4 | 5.9 |
| assay format | 1 | 2 | 5.2 |